Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio Inc. (NASDAQ: BOLD) is a clinical-stage oncology innovator developing ecDNA-targeted therapies for cancers driven by oncogene amplification. This page provides investors and researchers with essential updates on the company’s clinical programs, strategic initiatives, and scientific advancements.
Access authoritative reporting on Boundless Bio’s lead candidate BBI-355 (CHK1 inhibitor), diagnostic innovations like the ECHO assay, and pipeline developments. Our curated news collection covers critical milestones including trial results, regulatory submissions, and research collaborations.
Key updates focus on ecDNA-directed therapeutic progress, financial disclosures, and operational developments. Content is rigorously verified to support informed decision-making for stakeholders tracking oncology innovation.
Bookmark this page for real-time updates on Boundless Bio’s efforts to transform cancer treatment through its novel approach to targeting extrachromosomal DNA mechanisms.
Boundless Bio (NASDAQ: BOLD), a clinical-stage oncology company, reported its Q1 2025 financial results and business updates. The company ended Q1 with a strong cash position of $138.3 million, providing runway into 2027. Key highlights include:
The company anticipates initial proof-of-concept data from its BBI-355 Phase 1/2 POTENTIATE trial in oncogene-amplified cancers in H2 2025. Their novel Kinesin program is progressing, with development candidate nomination expected by mid-2025 and IND filing planned for H1 2026.
Financial results show R&D expenses of $12.1 million (down from $13.1M in Q1 2024), G&A expenses of $5.2 million (up from $3.8M), and a net loss of $15.8 million (compared to $15.4M). The company also presented promising preclinical data for BBI-825, showing potential in preventing resistance in colorectal cancer models when combined with RAS inhibitors.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, has announced its participation in the upcoming Needham Virtual Healthcare Conference.
The company's President and CEO, Zachary Hornby, will deliver a presentation on Thursday, April 10, 2025, at 1:30 p.m. ET. Investors and interested parties can access both the live and archived webcasts of the presentation through the 'Events & Presentations' section of Boundless Bio's website or directly via the provided webcast link.
Boundless Bio (BOLD) has reported its Q4 and full year 2024 financial results, highlighting progress in its oncology pipeline targeting extrachromosomal DNA (ecDNA) in cancer treatment. The company's lead candidate, BBI-355, is advancing in the Phase 1/2 POTENTIATE trial, with initial proof-of-concept data expected in H2 2025.
Key financial metrics include a strong cash position of $152.1 million as of December 31, 2024, providing runway into 2027. Full-year 2024 results showed R&D expenses of $55.3 million and G&A expenses of $18.0 million, with a net loss of $65.4 million.
The company is also progressing with its novel Kinesin program, targeting ecDNA segregation, with development candidate nomination expected by mid-2025 and IND submission planned for H1 2026. Additionally, Boundless appointed Robert Doebele, M.D., Ph.D., as Chief Medical Officer in February 2025.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology research for treating oncogene amplified cancers, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's President and CEO, Zachary Hornby, will engage in a fireside chat session scheduled for March 12, 2025, at 11:20 a.m. ET in Miami, FL. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website under the Events & Presentations section in the Investors area.
Boundless Bio (Nasdaq: BOLD) has appointed Robert ('Bob') Doebele, M.D., Ph.D., as Chief Medical Officer. Dr. Doebele brings over 15 years of oncology drug development experience to the clinical-stage oncology company, which focuses on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers.
Dr. Doebele was previously co-founder and Chief Scientific and Medical Officer at Rain Oncology (acquired by Pathos AI), where he led development of precision oncology therapies. His notable achievements include leading research at the University of Colorado that pioneered the TRK inhibitor field, contributing to the approval of Vitrakvi® and Rozlytrek®.
At Boundless Bio, Dr. Doebele will oversee the advancement of the BBI-355 Phase 1/2 POTENTIATE trial and the selection of a development candidate for the company's Kinesin program.
Boundless Bio (BOLD) announced significant updates to its pipeline and leadership team. The company has decided not to advance BBI-825 into Part 2 of the STARMAP trial due to pharmacokinetic data concerns and increasing development costs. However, enrollment continues for BBI-355's Phase 1/2 POTENTIATE trial, with initial clinical data expected in H2 2025.
The company's third ecDTx program is progressing, targeting a novel kinesin for ecDNA segregation, with development candidate nomination expected by mid-2025 and IND submission planned for H1 2026. Leadership changes include the departure of CMO Klaus Wagner and CBO Neil Abdollahian, with James L. Freddo appointed as Interim CMO. The company's operating runway has been extended into 2027.
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and oncogene amplified cancers, has announced its participation in Piper Sandler's 36th Annual Healthcare Conference.
President and CEO Zachary Hornby will participate in a fireside chat on Wednesday, December 4, 2024, at 3:30 p.m. ET in New York. The session will be available via live and archived webcast through the company's website under the Investors section.
Boundless Bio (BOLD) reported Q3 2024 financial results, highlighting progress in its clinical trials. The company maintains a strong cash position of $167.1 million, providing runway into Q4 2026. Key developments include ongoing enrollment in BBI-355 POTENTIATE and BBI-825 STARMAP trials, with initial proof-of-concept data expected in H2 2025. Q3 financials show R&D expenses of $14.1M (up from $11.6M in Q3 2023), G&A expenses of $4.6M (up from $3.3M), and a net loss of $16.5M (increased from $13.2M).
FAQ
What is the current stock price of BOUNDLESS BIO (BOLD)?
What is the market cap of BOUNDLESS BIO (BOLD)?
